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Structure-Activity Relationships of Inhibitors of

Polyglutamine Aggregation
Erin Newby
Senior Honors Project
August 2003

ABSTRACT
The presence of an expanded polyglutamine (polyGln) domain in the huntingtin protein
underlies the pathogenic events in Huntington's disease (lID), a neurodegenerative disorder for
which no cure exists. The ability of the expanded polyGln domain to form insoluble aggregates
appear to be critical in the lID pathogenesis, indicating that polyGln aggregation is a potential
target in the development for a cure.
Wetzel and colleagues have established a highly sensitive, fast, reproducible and specific
polyGln aggregation assay capable of following the ability of very low amounts of polyGln
aggregates to recruit additional polyGln peptides. Sub-micromolar concentrations of synthetic
polyGln aggregates are coated on a 96-well plate and are incubated for different times with
nanomolar amounts of biotinylated polyGln peptide. Europium-streptavidin addition and timeresolved fluorescence allow them to quantify the amount in femtomoles of polyGln peptide
incorporated into aggregates. They refined this microtiter plate assay as a screening assay for
aggregation inhibitors. In screening application, the assay can detect with reproducibility a 100
J.lM compound inhibiting a polyGln aggregate extension reaction by a factor of 2 or more (i.e. ~
50% inhibition).
Of over one thousand compounds of the NINDS (National Institute of Neurodegenerative
Disorders and Stroke) library tested with the microtiter plate assay, nine compounds were
revealed as potential inhibitors of polyGln aggregation and their ICso values were determined.
Interestingly, when other groups used different screening assays (worm model, cell based assay,
etc.) to test the NINDS library, they identified some of these hits and/or other compounds. In
this project, we propose to study the structures of the nine hits identified by Wetzel's laboratory
and to compare them to the database of all compounds tested for compounds with structural
similarities. If we find compounds with similar structures, we will determine their ICso value.
These results will help us in the determination of requisite chemical groups for inhibiting
polyGln aggregation. We also propose to look at the hits of the other groups and to compare
them to these nine potential polyGln aggregation inhibitors to determine if compounds with
common structures can act as inhibitors for different targets. These structure-activity
relationship studies are important for defining potential therapeutic agents and serve as a starting
point for designing and synthesizing more active analogs.
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INTRODUCTION
1 - Clinical Symptoms
Huntington's disease (lID) is a rare disease of hereditary transmission that only affects
about 0.01 % of the population. The initial manifestations are often behavioral and the diagnosis
may not be evident for months or years until the classical movement disorder develops. The
prominent characteristics of the disease include chorea, defined as "random purposeless
involuntary movement," and bradykinesia, or abnormally slow movement, which is often seen in
the early stages (1). The choreiform movement disorder is progressive, affects the extremities
and face, and it is associated with slowness and clumsiness of fine movements and postural
instabilities. In the late stages of the disease, dystonia sets in the muscles in the face, neck, or
limbs, which contract indefinitely, leaving the person rigid and bedridden. These movements are
due to neuronal dysfunction and loss. Post-mortem examination of lID patients show significant
shrinkage of the brain that can be up to 20% in advanced cases (2). Onset of the disease usually
occurs between 35 and 42 years of age, and affected individuals usually die about 17 years after
onset (2).
No cure exists for lID patients. Dopamine antagonists, which balance out the direct and
indirect neuronal pathways involved in controlling motor function, may be administered to
patients to relieve the symptoms of chorea. However, as the striatal output neurons die, the
dopamine antagonists become less effective in suppressing choreic movement (2).
Antidepressants can also be prescribed to alleviate emotional and behavioral symptoms, but this
medication possesses the side effect of increasing bradykinesia.
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2 - Molecular aspects
2.1 - Mutant huntingtin and aggregation
In 1993, an international group of scientists identified the mutation in the gene interesting

transcript 15 (!T15) responsible for the disease (3). The gene !T15 is composed of 67 exons and
encodes a protein of 3,144 amino acids, called huntingtin. Exon 1 contains a CAG trinucleotide
repeat that encodes the amino acid glutamine.

In healthy individuals the number of CAG

repeats, i.e. polyglutamine length is 10 to 34, whereas in lID patients the number increases to 40
or more. In juvenile cases, the number is generally higher than 55 repeats and the mutant gene
generally comes from the father. Studies show that huntingtin is expressed in the cytoplasm of
most cells in the body. In the brain, huntingtin is found predominantly in the cytosol of neuronal
cells and seems to playa vital role in development, as knockout mice do not survive beyond the
eighth day of embryogenesis.

Curiously, mutant huntingtin that contains an expanded

polyglutamine (polyGln) sequence is not only found in the cytoplasm but also in the nucleus,
where it tends to aggregate and form inclusions in the neurons of lID patients (4). This same
phenomenon has been observed in yeast and transgenic animals (5,6,7). The trend concerning
these stretches indicates that the more glutamine (GIn) repeats in the gene, the earlier the onset
and the more severe the symptoms. Nine other polyGln disorders similar to lID have been
identified, including Kennedy's disease and the spinocerebellar ataxias types 1,2, 3 (also known
as Machado-Joseph disease), 6, 7, and 17. In each of these disorders, the disease is dependent on
increased polyGln length in a particular protein that consequently forms insoluble aggregates.
Neuronal loss is noted in all of the polyGln disorders, with each disease targeting specific areas
of the brain.

The repeated presence of aggregates and neuronal death suggests that the

aggregates are involved in the pathology of the polyGln diseases.
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One hypothesis as to the reason for aggregation was proposed by Max Perutz and
colleagues in a paper concerning the secondary structure of the mutant protein (8). Building on
the newfound discovery that HD exists in patients expressing mutant huntingtin protein in excess

of 41 glutamine residues, Perutz and colleagues created a computer-generated model
demonstrating that the secondary structure of the polyGln aggregate consists of antiparallel

~

strands. Perutz presented the idea that the strands form hairpin structures that associate with one
another through hydrogen bonding in the aggregation process. The team used this model to
synthesize a polyGln peptide and added charged amino acids to each terminus to make the
protein more soluble in an acidic environment. At neutral pH, the protein precipitated into
aggregates, which were analyzed by several methods to elucidate the secondary structure.
Circular dichroism as well as X-ray diffraction confirmed a structure of

~-pleated

sheets,

although the possibility of hairpins could not be explored.
Once the polyGln

~-pleated

sheets have formed, they accumulate into an inclusion body

and aggregate formation occurs. Studies by Scherzinger and colleagues involving glutathione-Stransferase-lID exon 1 fusion proteins show that insoluble huntingtin aggregates require a
nucleus or "seed" and a critical concentration of protein to begin the aggregation process (9). An
analysis of the aggregation kinetics by Chen and colleagues confirmed the proposal that
aggregation occurs by nucleated growth polymerization, and the nucleus was found to be
monomeric (12). This monomer is thought to exist as a highly ordered
aggregated

~-sheets

~-sheet

structure, and the

have been proposed to assume a more ordered, fibrillar, tertiary

structure(12). Among the many models for amyloid fibril structure is one proposed by Perutz
and colleagues in one of Perutz's last papers (13). As illustrated in a review by Wetzel, evidence
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supports the model of a p-helical structure, which displays greater stability than the p-sheets
themselves (14).
2.2 - Recruitment: the aggregation process

As a "seed" recruits mutant huntingtin to form an aggregate, other proteins may be
sequestered in the aggregate that are vital to cell function. The fibrils' resistance to protease
activity prevents the release of these functional proteins from the aggregate and the lack of
essential proteins disrupts the cell's response to stress. Ross and colleagues found that in lID
cell-culture models, lID transgenic mice, and human lID post-mortem brains, nuclear CBP
levels drop in correlation with the detection of CBP in intranuclear polyGln aggregates (17). The
lack of CBP leads to dysregulation of CBP-activated transcription, which may account for the
toxicity of aggregates localized in the nucleus (18). Other proteins have also been found in
intracellular aggregates, including the molecular chaperones Hsp70 and Hsp40, along with the
proteasome components ubiquitin and the 20s and 19s complexes (18). The expression of Hsp40
and Hsp70 suggests that the cell recognizes the polyGln aggregates as misfolded conformers and
that the cell then upregulates the transcription of the heat shock protein genes in an attempt to
stop further polymerization. Increased expression of these heat shock proteins has been shown
to suppress the neurotoxicity caused by polyGln aggregates in transgenic animal models (19, 20),
even though intracellular inclusions are still present. Muchowski and colleagues found that the
inclusions contain Hsp40 and Hsp70 bound to soluble aggregates, which may be subject to
protease activity (21). However, when the cell has aged significantly, the production of these
chaperones decreases.

Hsp40 and Hsp70 continue to associate with mutant huntingtin at a

constant rate, leading to chaperone depletion within the cell. The mutant protein concentration is
then high enough to overcome these quality-control mechanisms and form ordered fibrils (18).
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Additional misfolding by other cellular proteins may also result in neutral or damaging effects
due to the absence of chaperones throughout the cell.

2.3 - Toxicity of the polyGln aggregates
Experiments show that the expanded tract has a toxic quality as the expression of
extended polyGln tracts, either alone or in the context of a larger protein, causes symptoms of
neurological dysfunction in mice (11). Amyloid-like fibrils have been observed in models of
expanded CAG repeat diseases such as transgenic mice, Drosophila, C. eZegans, and yeast, and
in HD patient brains (10).

In each of the models as well as in HD patients, a noticeable

retardation of movement and general neurological dysfunction is observed.

Because these

effects are always found in correlation with the presence of insoluble aggregates, some
aggregated form of polyGln may be essential to the neuronal destruction observed in HD.
Although the recruitment mechanism and sequestration of essential proteins have been presented
as possible means through which aggregates affect cell death, other hypotheses are still under
investigation. Among these hypotheses is the idea that the inclusion bodies of accumulated
fibrils interfere with normal cell function and induce apoptosis (2).

3 - The search for a cure
Because polyGln aggregates have been observed repeatedly in correlation with neuronal
loss, aggregates are implicated in the progression of the disease. The current theory in a number
of laboratories is that the reduction or prevention of mutant huntingtin aggregation will lead to
the development of a cure. Several assays have been designed to find molecules that can inhibit
polyGln aggregation. Heiser et aZ. studied the effects of antibodies on aggregation, specifically
the monoclonal antibody lC2 that successfully prevented the formation of fibrils in vitro (15).
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As a result of the added antibodies, soluble aggregates containing protein and antibodies were
found, and these aggregates were vulnerable to protease activity. This effect suggests that the
antibody works as a chaperone to stabilize the native conformation of the expanded polyGln tract
and inhibit nucleus formation (15).

Another potential inhibitor of aggregation is an

oligonucleotide, as explored in the work of Nellemann et al (16). Realizing the importance of a
critical concentration of protein necessary to begin aggregation, Nellemann used antisense
oligodeoxynucleotides to downregulate the expression of mutant huntingtin.

Although this

process proved effective in vitro in the context of PC-12 cells, the oligodeoxynucleotides were
instable in vivo and showed difficulty passing the blood-brain barrier (16). In other attempts to
prevent aggregation,

a

wide

variety

of chemical

compounds,

including

hormones,

antidepressants, antibiotics, and potential inhibitors of ~-amyloid formation are being tested for
inhibition activity.
A library of lOOO-plus compounds with pharmacological properties such as
antidepressants, hormones, and antibiotics was compiled by the National Institute for
Neurological Disorders and Stroke (NINDS) and made available to research laboratories for
blind studies. Teams from various labs tested these compounds in the context of cell-based,
animal model, and synthetic assays to find inhibition values for cell toxicity, animal responses,
and polyGln aggregate extension. The compounds deemed most successful in each assay, or
"hits," were reported to the NINDS, and the compounds' chemical natures were revealed to the
labs.
Due to the vast number of molecules to be tested for inhibition capability, assays known
as high throughput screening assays have been developed to examine large quantities of
molecules in a short amount of time. Wetzel and colleagues have designed such a screening
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assay using synthetic peptides to test the recruiting ability of polyGln aggregates (22).
Nanomolar amounts of biotinylated peptide are added to aggregates in a microtiter plate, which
is incubated for a period of time to allow extension of the aggregate. The amount of peptide
incorporated into the aggregate can be determined with the addition of a europium-streptavidin
solution, and a microtiter plate reader detects the fluorescent europium. If a chemical compound
is added along with the peptide, one can detect the compound's ability to inhibit polyGln
extension by comparing the amount of peptide integrated in the aggregate to the amount that
integrated without the presence of the compound. Previously, in participation with the NINDS
study, compounds from the NINDS library were screened using this method. Nine compounds
exhibited greater than 50% inhibition at 100 IlM (V.Berthelier & R. Wetzel, unpublished results),
and these compounds were further tested to determine their ICso values.
To determine which chemical groups confer an inhibition activity, we inspected the
database of all the compounds tested for structures similar to these nine hits. We conducted
dose-response analysis of structurally related non-hits to quantify weak activities. In order to
explore the possibility that some chemical groups may have inhibitory effects on more than one
target, we compared our nine hits to hits found in the different types of assays testing for polyGln
aggregation and/or toxicity. In comparing our hits to the hits reported by other labs, we were
looking for structural similarities to highlight compounds that were possibly overlooked in the
screening process because the inhibition values were just below the minimum standard of 50%
inhibition. We also correlated the effects of compounds in vitro (in the extension assay) to the
effects noted in vivo in a C. elegans model of polyGln disease.
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MATERIALS AND METHODS
1 - General Materials
PolyGln peptides were obtained from the Keck Center at Yale University, where custom
solid-phase synthesis was used to construct peptides according to the design K2QnK2. The
structures and purities of the peptides were confirmed by mass spectrometry at the Keck Center.
Biotinylated polyGln peptides were prepared by N-terminal derivatization during solid-phase
synthesis.
2 - Purification and preparation of biotinylated polyGln peptides

Established methods were used to prepare the biotinylated peptides and aggregates (22).
Biotinyl K2Q28K2 peptides were dissolved at 0.5 mg/ml in a mixture of 50% trifluoroacetic acid
and 50%1,l,l,3,3-hexafluoro-2-propanol (TFAJHFIP), agitated, and incubated at room
temperature for 30 minutes. After evaporating the volatile solvents under a stream of argon in a
fume hood, the peptides were dissolved in H20ffFA, at a pH of 3, to 0.5 mg/ml. Reverse-phase
high-performance liquid chromatography (HPLC) was used to determine the exact peptide
concentration, by comparing the peak area at 215 nm to a previously established standard curve
of K2QlSK2. The biotinylated peptide was diluted to 10 nM in extension buffer, aliquoted, snapfrozen, and stored at -80°C. Peptides are prepared fresh each month for use in the ICso assay.

3 - Preparation of polyGln aggregates
The dissolved K2Q28K2 peptide obtained from HPLC was adjusted to 10

~

and lOX

PBS added to raise the pH to 7.4. This peptide solution was then incubated at 37°C for 24 hours,
followed by incubation at -20°C for 24 hours. The aggregates formed during incubation were
characterized by Thioflavin T fluorescence and light scattering and were then centrifuged at
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20,800g for 30 minutes at 4°C. The collected aggregates were resuspended in extension buffer
and aliquoted into Eppendorf tubes, which were snap-frozen and stored at -80°C.
4 - Preparation of aggregate plates
PolyGln aggregates were fixed to 96-well microtiter plates by adsorption.

Each

microplate was coated with aggregates diluted in extension buffer to 40 ng per well and
incubated, uncovered, at 37°C for 17 hours.

Plates were used immediately following this

incubation period.
S - The ICso assay
A freshly prepared 0.3% gelatin solution was added to a coated microplate, at 100 III per
well, and the plate was incubated for 1 hour at 37°C. The gelatin solution was removed from the
plate by washing the wells three times with extension buffer. Biotinylated peptide was then
added to the plate at a concentration of 10 nM per well. In the ICso assay, a serial dilution
ranging from 1.5625 to 200

~

is made of each compound, and each dilution is added in

triplicate to the plate with the aggregates and peptide. A streptavidin-europium complex is then
added, and after an incubation period, the excess is washed out. The bound europium (Eu3+) is
released by addition of a chelation buffer, and the released Eu3+ counted by time-resolved
fluorescence, which allows us to determine the amount of biotinylated peptide that added to the
aggregate during the incubation period. By comparing the Eu3+ incorporation in the presence of
an inhibitor to incorporation in its absence, inhibition values of the compounds at each
concentration are calculated and used to create a dose response curve. The concentration of
potential inhibitor at which the aggregate elongation is inhibited by 50% is recorded as the IC so
value.
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RESULTS AND DISCUSSION
1 - Structure-activity relationships of NINDS hits
From previous screening assays, nine compounds, or "hits", were identified that inhibited
greater than 50% at 100 !JM concentration. In reviewing the structures of the nine hits (Figure
1), we found that some structural features were repeated such as benzene rings with cis hydroxyl
group substitutions, p-Iactam rings, isolated phenol groups, and quinones. Using these structures
as criteria, the database was searched for similar compound structures that might be expected to
also exhibit inhibitory activity.
We compiled six groups of additional compounds from the database chosen to represent
certain structural features. These groups of structures included benzene rings with cis hydroxyl
groups, quinones, p-Iactam rings and isolated phenol rings, large multi-faceted ring structures,
methacycline derivatives, and steroid hormones.
One common feature suggested by this exercise that might be related to inhibition
activity is a phenol group, which might playa role in binding interactions with the aggregate.
We chose several compounds from the library that contained this group, including the previous
hit moxalactam disodium, as well as the compounds isoxsuprine hydrochloride and cefoperazole
sodium (Figure 2). We completed microplate assays to determine the IC so values for isoxsuprine
and cefoperazole, and as indicated in Table 1, these values were found to be 198 and 296 p,M
respectively.

These IC so values are rather high in comparison to the ICso of moxalactam

disodium determined previously to be 1!JM. (However, a repeat analysis of fresh moxalactam
disodium revealed an ICso of 398 p,M; the reason for this discrepancy is unclear.) The phenol
hydroxyl group may bind to a portion of the aggregate to disrupt the stability of the hydrogen
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bonds in the aggregate structure, or the hydroxyl group may bind to glutamine's polar side chain
to prevent further hydrogen bonding with other peptides in the aggregate.
Another phenolic compound selected from the database was tyrothricin (Figure 2). We
found that this compound exhibits an IC so of 272 11M. The size of the ring itself may act as an
obstruction for additional binding of peptides; alternatively, its activity may be limited to its
phenol moiety.

2 - Comparison of the nine hits with hits of other assays
Compounds with structural similarity to our nine hits were also found in hits reported to
the NINDS by other laboratories in the consortium. These included lysyl-tyrosyl-Iysine acetate
and meclocycline sulfosalicylate. We determined the IC so values for these compounds (Table 1).
Lysyl-tyrosyl-Iysine acetate (Figure 2) contains a phenol

Table 1

Compound
Isoxsuprine HCI
Tyrothricin
Cefoperazole Na
Lysyl-tyrosyl-lysine Acetate
Meclocycline Sulfosalicylate

ICso
198IJM
272IJM
296 IJM
330 IJM
No effect

group in analogy to moxalactam disodium, isoxsuprine
hydrochloride, and cefoperazole sodium. The IC so value
found for lysyl-tyrosyl-Iysine acetate is also comparable

to the values for these other compounds containing a phenol group, suggesting that the structure
plays a similar role in inhibiting aggregate elongation in each of these compounds.
Meclocycline differs from methacycline, which has an ICso value of 123

~M,

by only a

chlorine atom substituted in place of a double-bonded CH2 group (Figure 3). Based on this
structural similarity, we believed that meclocycline's activity would equal that of methacycline;
however, our results show no effect by meclocycline up to a concentration of 200

~M.

This may

be due to the interaction or interference of the counterion sulfosalicylate; alternatively, the
additional chlorine atom may destabilize the compound by drawing electrons from the oxygen
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atom in the hydroxyl group on the opposite side of the benzyl ring, making the compound more
acidic. This added quality may disrupt the type of interactions with the aggregate that makes
methacycline a good inhibitor.

3 - Comparison with hits from an in vivo assay
Among the lab teams who tested the compounds of the NINDS library was a group led by
Dr. Christian Neri. Neri and his colleagues used a Caenorhabditis elegans model in which the
mutant protein is expressed in the worm. When the affected worms are prodded by a small rod,
little to no response is observed, compared to the reflexive retraction observed in normal worms.
Neri developed a screening assay to determine the effects of compounds on the aggregation
process by growing the worms in microplate wells containing a known concentration of the
compounds. The worms mature in about 72 hours, at which point they are placed under the
microscope and their physical responses observed as they are prodded with the rod. Recovery of
a retractive response indicates the compound's effect in suppressing the disease state, which may
be due to its effect on polyGln aggregation. The compounds are then ranked according to their
EC50 values, or the concentration of the compound necessary to achieve 50% of the observed
effect. Among the most effective compounds in Neri's assay are those listed in Table 2.
In order to compare our assay results to those of Neri's group, we completed assays to
find IC 50 values for the group of compounds that exhibit the highest activity in the in vivo assay
(Table 2).

We chose the 13 compounds considered most potent with C. elegans (C. Neri,

personal communication) and upon inspection of these 13 compounds, we immediately
recognized one hit from our own assay, protoporphyrin IX. We then completed dose response
curves for the remaining 12 compounds and found additional structures that exhibited inhibition
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activity in the extension assay (Figure 5). As determined in previous studies (V. Berthelier & R.
Wetzel, unpublished), the quinones such as ellagic acid tend to show good ICso values, as
confirmed by the value for quinalizarin of 91

~M

(Figure 4). This earlier study also contrasted

oxidized quinone compounds with the dihydroxyquinone form and found that the reduced form
of the compounds was less effective in inhibiting elongation of the aggregates. Compounds with
hydroxyl groups in cis formation on a benzyl ring were also hypothesized to be more effective
than compounds with cis hydroxyl groups on a ring other than benzene, and the high ICso value
determined for naringin (Figure 4) of 7.8 mM in comparison to the ICso values for ellagic acid
and quinalizarin, 48 and 91

~

respectively, supports this theory. In addition, the phenol group

in naringin does not appear to playa role in the compound's activity such as that of the other
phenolic compounds studied.
Of the 12 compounds active in C.

Table 2
Wetzel

elegans that we tested, the best ICso value

Compound

Protoporphyrin IX
obtained in the microplate assay was for the Cephalosporin C
Quinalizarin
antibiotic cephalosporin C, which contains a ~- Perphenazine
Nortriptyline
lactam ring and two carboxyl groups (Figure Oxolinic Acid
Ebselen
5).
As noted above, another effective Cannabidiol
Naringin
compound consisting of a ~-lactam ring and MCI-186
Celastrol
carbonyl groups in cis formation on a Glibenclamide
Tertenadine

ICso

Neri

ECso

12 J.lM
0.005 J.lM
79 J.lM
2.000 J.lM
91 J.lM
2.800 J.lM
125 J.lM 1.000 IJM
133 J.lM 1.800 IJM
321 J.lM 2.300 IJM
408J.lM 0.200 IJM
743J.lM 0.020 J.lM
7.8mM 0.800 J.lM
252mM 0.016 J.lM
No effect 00400 J.lM
No effect 2.300 J.lM
No effect 0.900 J.lM

substituted benzene ring is cefoperazole
sodium (ICso = 296 J.tM).

In previous hits observed in the extension assay (Figure 1),

moxalactam disodium was among the best inhibitors when the compound was stored for a period
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of time (ICso = 1 J.1M), making the p-Iactam ring, or possibly the decomposition products of the
p-Iactam ring, a structure of interest.
Other C. elegans-active compounds that exhibited noticeable activity in the in vitro assay
include nortriptyline and perphenazine (Figure 6). The structures of these two compounds are
analogous to the structure of the hit hycanthone found by the Wetzel group (Figure 1).
Hycanthone, perphenazine, and nortriptyline all have hydrophobic, aromatic groups containing
an amino alkyl appendage that, when protonated in aqueous solution at neutral pH, would be
expected to have the properties of ionic detergents. The structure of oxolinic acid (Figure 6) also
resembles hycanthone, except that the aminoalkyl appendage is shorter. This difference may
make oxolinic acid a weaker ionic detergent and consequently a weaker inhibitor of polyGln
aggregation, as shown by the higher ICso value (321
hycanthone, nortriptyline, and perphenazine (50

J.1M,

~M)

in comparison to the ICs o values of

133

~M,

and 125

~M).

A possibility for

further confirmation of the activity of this ionic detergent structure is testing the other
compounds in the NINDS library that are similar to nortriptyline.
The structures of ebselen and MCI-186 are unlike the previous hits of the Wetzel group.
What makes these two compounds effective in interaction with the polyGln aggregates is
unclear. Both ebselen and MCI-186 were among Neri's most active compounds (Table 2) but
gave only rather unimpressive IC so values in the microtiter plate assay. It is possible that
metabolic processing in the worm may enhance the activity of these compounds in vivo.
Among the less reactive and ineffective compounds are celastrol, terfenadine, and
glibenclamide. The lack of activity by celastrol was not surprising, as past attempts at finding an
active steroid ring structure have proven fruitless, with the exception of ethinyl estradiol. As in
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the cases of ebselen and MCI-186, the structures for terfenadine and glibenclamide do not
possess any of the functional groups present in the Wetzel group's hits.

CONCLUSIONS
The information gained from this study does not reveal any strong relationship between
the in vitro and in vivo assays, as illustrated by a graph (Figure 7) constructed to relate the 1Cso
and ECso values of the top 8 compounds (protoporphyrin IX to cannabidiol). A more definitive
test, however, would be to determine dose response curves and 1Cso values for all lOOO-plus
compounds in the NINDS collection. It may be that there is a statistically significant overlap
among the compounds active in these two assays.
Our studies reveal the potential for activity by compounds containing a p-Iactam ring,
with the emphasis on the fact that the decomposition products may be the source of the
compounds' activity. A project that could possibly confirm this idea would be one in which a
collection of p-Iactam antibiotics are obtained, tested to determine the IC so values, and then
oxidized. The compounds should be tested again to look for a gain of activity. Another possible
follow-up study could be a series of assays to determine the activity of hydrophobic structures
resembling perphenazine and nortriptyline.

The IC so values that we determined for these

compounds are close to the values found for the hits ethinyl estradiol and methacycline in
previous studies.
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Figure 1. The values listed for each compound include 1)
the ICso value obtained from assays performed using the
compound received from NINDS, and 2) the 1Cso value
determined from follow-up assays completed using the
same compounds obtained commercially. These values can
be viewed as a comparison between compounds that were
stored for a period of time in DMSO and compounds that
were reconstituted just before conducting the assay. When
only one value is listed, it is the inhibition value of the
compound originally received from the NINDS (no
commercial compound available).
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Figure 2. Structures containing phenol hydroxyl groups.
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Figure 3. Structural similarity between methacyc1ine and mec1ocyc1ine sulfosalicylate.
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Figure 4. Structural comparison of quinalizarin and naringin.
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Figure 5. Structures for the 13 most active compounds with C. elegans, and comparison ofICso values found in the
Wetzel group's microplate assay with ECso values found in Dr. Neri's work with C. elegans.
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Figure 6. Structural similarity of nortriptyline, perphenazine, and oxolinic acid to hycanthone.
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Figure 7. Linear regression graph of the first 8 compounds from Table 2 (protoporphyrin IX to
cannabidiol) to show relationship between ECso values in C. elegans testing (x-axis) and ICso
values in the microtiter plate assay (y-axis).
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